Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80
Document › Details

Polyphor Ltd.. (9/17/15). "Press Release: Polyphor and Taisho Enter into Research Collaboration on Novel Drug Candidates". Allschwil.

Organisation Organisation Polyphor Ltd. (SIX: POLN)
Products Product drug discovery
  Product 2 macrocycle technology platform
Index term Index term Taisho–Polyphor: drug discovery, 201509– collab €na identification of drug candidates using macrocycle platform
Persons Person Altorfer, Michael (Swiss Biotech Association 201811 CEO before Polyphor + Roche + Ciba-Geigy + Sandoz + UBS Warburg)
  Person 2 Kaul, Adesh (Basilea 201803– Chief Corp Dev Officer before Polyphor + Basilea + Genedata + Neue Züricher Bank)

Polyphor Ltd, a privately held pharmaceutical company specialized in the discovery and development of macrocycle drugs, today announced the signing of a research collaboration agreement with Taisho Pharmaceutical Co., Ltd, a fully owned subsidiary of Taisho Pharmaceutical Holdings Co., Ltd, listed on the Tokyo Stock Exchange. The parties will collaborate on the identification of novel drug candidates based on Polyphor’s proprietary macrocycle platform.

Michael Altorfer, Ph.D., CEO of Polyphor, said: “Taisho has a long history and an impressive track record in the discovery, development and commercialization of innovative drugs. Polyphor’s proprietary research program will benefit in scale and scope from this collaboration as well as through Taisho’s specific expertise. This marks another important step on our way to fully exploit the potential of our unique macrocycle platform and to build a broad portfolio of compounds with the potential to be first-in-class or best-in-class in areas of high unmet medical need.”

Financial details were not disclosed.

About Polyphor Ltd:

Polyphor is a Swiss Pharma company focusing on the discovery and development of macrocycle drugs addressing high unmet medical needs. Macrocycles represent a new drug class complementary to the traditional small molecules and large biopharmaceuticals. Polyphor leverages its unique and proprietary technology platforms to develop its own product portfolio and to pursue licensing and collaboration opportunities with industry partners. The company’s lead drug candidates include POL6326, Balixafortide, (Phase II), a CXCR4 antagonist, for tissue repair and combination treatments in oncology; POL7080 (Phase II), a highly specific antibiotic with a novel mode-of-action to treat Pseudomonas infections; and POL6014 (Phase I), an inhaled inhibitor of neutrophil elastase for the treatment of Alpha-1 Antitrypsin Deficiency, Cystic Fibrosis, and other lung diseases. Polyphor is a privately held company with about 100 employees, headquartered in Allschwil, near Basel. For additional information, please visit


Adesh Kaul
Head Corporate Development
Polyphor Ltd
t: +41 61 567 16 00; e:

Polyphor Ltd, Hegenheimermattweg 125, CH-4123 Allschwil, Switzerland, Tel. +41 61 567 16 00, Fax +41 61 567 16 01,

Record changed: 2019-06-09


Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for Polyphor Ltd. (SIX: POLN)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81

» top